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Abstract: Catecholamines play an important regulatory role in cutaneous wound healing. The exact
role of dopamine in human epidermis has yet to be fully elucidated. Current published evidence
describes its differential effects on two separate families of G protein coupled receptors: D1-like and
D2-like dopamine receptors. Dopamine may enhance angiogenesis and wound healing through its
action on dopamine D1 receptors, while impairing wound healing when activating D2 receptors.
This review summarizes the evidence for the role of dopamine in wound healing and describes
potential mechanisms behind its action on D1 versus D2-like receptors in the skin.
Keywords: wounds; dopamine; wound healing
1. Introduction
Wound healing occurs as a normal physiological response to cutaneous damage, either from acute
trauma or underlying disease, leading to skin breakdown and ulceration. The process of cutaneous
wound healing consists of several phases, including an inflammatory phase, a proliferative phase,
and a remodeling phase, all of which rely on communication of various cells and signaling molecules.
Any defect in the steps involved can impair tissue regeneration and lead to poor wound healing.
The skin contains a rich supply of nerves, with nerve endings in the dermis, extending
into the epidermis, as well as surrounding blood vessels, pilosebaceous units, and sweat glands.
Several studies have shown that nerves play an important regulatory role in cutaneous wound
healing [1–3]. Nerves can contribute to the inflammatory response in the first phase of wound healing,
by releasing endogenous catecholamine neurotransmitters, such as epinephrine, norepinephrine, and
dopamine (DA) [4]. Human keratinocytes also have the capability to utilize L-tyrosine to synthesize
L-DOPA, subsequently resulting in the production of dopamine, norepinephrine, and epinephrine [4].
DA is not only pivotally important in the central nervous system for emotion, cognition, and movement,
but it also has peripheral effects in regulating endocrine, cardiovascular, renal, gastrointestinal,
and immune system functions [5,6].
DA effects are mediated by five DA receptor subtypes, each a G-protein coupled receptor, with two
distinct signaling mechanisms that divides them into two separate families. Agonists of D1-like
receptors (D1 and D5 receptors) activate Gs proteins, which activate adenylyl cyclase and increase
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the intracellular concentration of cAMP. On the other hand, D2-like receptor (D2, D3, D4 receptors)
agonists stimulate G0/Gi proteins, thereby down regulating the intracellular cAMP pathway and
inhibiting neuronal activity (See Figure 1) [7]. Hereafter, D1-like and D2-like receptors will be referred
to as D1 and D2 receptors, respectively.
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Figure 1. D1 and D2 Receptor Pathways–D1 and D2 receptors are G-protein coupled receptors that
signal through different cascades. 1 receptor agonists lead to increased production of adenylyl cyclase
(AC) via a Gs pathway. Conversely, agonism of D2 receptors stimulates Gi proteins leading to decreased
cAMP and inhibiting neuronal activity.
DA receptors are also expressed on various cell types within the skin [8–10]. Fuziwara, et al.
demonstrated that DA plays a role in murine skin barrier homeostasis by acting on D2 receptors that
are present on epidermal keratinocytes, resulting in changes in their cAMP level that regulate barrier
function [11]. This study found differential expression of the D2 and D4 receptors within the basal and
outermost layers of the epidermis [11]. Other work has demonstrated the presence of D1 receptors in
dermal fibroblasts [9], and D2 receptors in endothelial cells [12]. Dopamine reaches the skin primarily
via nerve endings, but there is also evidence to suggest that keratinocytes express enzymes to both
synthesize and metabolize dopamine [11,13]. DA receptors have been identified on B cell and natural
killer cell membranes, and to a lesser extent, on T cells and monocytes [14]. However, the literature on
these cells is vast and conflicting, and is therefore not included in this review.
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DA’s role in cutaneous wound healing has become an important focus of investigation, although it
is hard to ascribe to it a strictly pro- or anti-reparative role because of divergent reported effects.
The purpose of this review is to highlight and summarize the evidence of dopamine’s role in wound
healing and to discuss potential mechanisms that underpin dopamine’s contribution to healing
of wounds.
2. Influence on Angiogenesis and Dermal Wound Healing
One necessary component of successful wound healing is angiogenesis, the formation of new
blood vessels. Angiogenesis occurs not only in wounds, but also during tissue remodeling in healthy
and diseased states. A delicate balance exists between pro-angiogenic and anti-angiogenic factors,
which dictates the formation of new blood vessels [15]. Angiogenesis is vital to the regeneration of new
tissue in wound beds by providing adequate nutrients and oxygen to aide formation of granulation
tissue [16,17]. It is mediated by VEGF-A, the primary cytokine stimulating the growth of neovessels in
wounds, in which it acts in a paracrine manner on VEGF-2 receptors in endothelial progenitor cells and
endothelial cells [18,19]. Both pro- and anti angiogenic responses and changes in VEGF-A in response
to activation of the DA receptors have been reported, and the differences are likely related to the DA
receptor being targeted and the cells in which they have been investigated.
Using eticlopride, a specific, a specific D2 receptor antagonist, Shome, et al. demonstrated
that excisional wounds in mice treated with this drug had a dose-dependent increase in wound
closure (maximally 78.3% by day 7, as compared to 38.2% in control mice) that was associated with
a statistically significant increase in wound microvessel density [20]. To further probe these results,
these investigators examined the expression of HoxD3, a transcription factor that is involved in
angiogenesis [21,22], and one of the genes for which it modulates expression, α5β1 integrin [23].
They found that eticlopride treatment increased HoxD3 expression and up-regulated α5β1 integrin in
wound bed tissue. Examining cultured human umbilical vascular endothelial cells (HUVECs) directly,
they found that treatment with 1 µM of DA (physiological concentrations at the neuronal synapse) [24]
blocked the vascular endothelial growth factor A (VEGF-A) -induced expression of HoxD3 and α5β1
integrin expression, while conversely, treatment with eticlopride restored HoxD3 and α5β1 integrin
expression. Since these studies were performed in HUVECs, rather than in murine dermal angiogenic
endothelial cells that would have been more relevant to the in vivo murine model, translating the
in vitro results to the in vivo findings may be challenging. Dopamine antagonists are widely used
clinically as antipsychotic drugs, so one could envision analysis of incidence of chronic wounds in this
patient population to determine if there is any association between the DA receptor antagonist use and
improved healing.
As opposed to receptor antagonism, the role of direct activation of the D1 receptor in
wound healing and angiogenesis was evaluated by Chakroborty et al. [9]. Excisional wounds in
streptozotocin-induced (type 1 model) diabetic mice healed more quickly in animals treated for
five days with specific D1 receptor agonists (SKF38393 or SKF81297), as compared to controls.
By day 11, wound closure reached 100% in the D1 receptor agonist treated mice, while wound
closure only reached 42% in the non-treated control mice. Furthermore, D1 receptor activation
significantly increased the expression of VEGF-A and angiogenesis in wounds of the diabetic mice
when compared to the untreated mice. Similar results were seen in the db/db (type 2 model) diabetic
mice. Interestingly, they found that the source of the increased VEGF-A in the wound was the dermal
fibroblast. Human dermal fibroblasts, isolated from the skin of diabetic patients increased their VEGF-A
production in response to D1 agonists. This was a surprising finding, since prior work had shown
that D2 activation of endothelial cells decreases, rather than increases, VEGF-A generation [25,26].
Thus, not only are there opposing responses to activation of different receptor types, but also different
cell types expressing the same receptor type can respond with directly opposing responses.
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3. Influence on Epidermis and Keratinocytes
Outside of the work demonstrating the role of DA in the epithelial pigmentation, there are
remarkably few studies investigating other potential roles in the epithelium. This is particularly
surprising given that epidermal keratinocytes express DA receptors [11], as well as synthesize DA [13].
One of the earliest studies in this area was that of Harper and Flaxman [27], who noted that dopamine
decreased keratinocyte mitosis in human epidermis and ascribed this to modulation of cAMP levels.
The more recent work of Fuziwara, et al. demonstrated that activation of the D2 receptor with topical
application of its agonist, bromocriptine, decreased epidermal proliferation, while the D2 receptor
antagonist, L-741626, conversely induced epidermal hyperplasia in barrier-disrupted mouse skin, with
an associated decrease in cAMP with bromocriptine treatment, and increased cAMP with the L-741626
treatment [11]. This is in agreement with other studies that have noted that increased cAMP levels
associated with decreased keratinocyte mitosis and proliferation [28–30].
On the other hand, this group found that the D2 agonist significantly accelerated barrier recovery
after tape stripping, while D2 receptor antagonists (L-741626, L-741742, and remoxidride) significantly
slowed the rate of barrier recovery. Since these changes were associated with decreased (agonist
treatment) or increased (antagonist treatment) cAMP levels, these findings extended the group’s
earlier work that noted that increased cAMP levels are associated with skin barrier disruption,
and the restoration of the barrier is associated with cAMP lowering drugs [31–33]. In addition,
the researchers further hypothesized that since D2 receptor antagonists delayed barrier repair,
there must be endogenously produced dopamine by keratinocytes, which was confirmed based
on an increase in DA level in the culture medium after keratinocyte incubation [11], confirming earlier
findings of DA generation by keratinocytes [13,34]. It is tempting to hypothesize that dopamine is
secreted by keratinocytes in response to barrier disruption or injury, and by virtue of its effects on
the D2 receptor localized in the uppermost layer of the epidermis, can hasten barrier repair and the
protective function of the epidermis, even at the cost of decreasing basal keratinocyte proliferation.
However, further experiments are needed to fully understand the dopamine-receptor interaction in
human epidermis.
Additionally, DA can alter the innate immune responses of keratinocytes by stimulating their
production of Il-6 and Il-8, which could also be a factor in modulation of the inflammatory response
required in the early phases of wound healing [35].
4. Influence on Mesenchymal Stem Cells
Wound healing requires the interaction of various regulatory molecules that are generated by
multiple cell types, such as endothelial cells, endothelial progenitor cells, and mesenchymal stem
cells (MSCs) [15,17,36,37]. MSCs, originating from a number of tissues including adipose tissue and
adult bone marrow, mobilize in response to chemokines that are released from various distant sites
in the body. In the case of wounds, the release of wound-generated growth factors and cytokines
mobilize and attract MSCs to the injured tissue [38,39]. This is important in cutaneous wound healing,
because MSCs can induce angiogenesis in healing tissues [37,40,41]. Therefore, it is important to
understand how dopamine can influence MSC biology.
DA D2 receptor antagonism enhances mobilization of MSCs into wound tissue beds [42].
Shome et al. compared the numbers of MSCs (CD34−, CD35−, CD105+) in peripheral blood in
D2 antagonist treated mice versus controls [42]. Wounded mice that were treated with eticlopride
(a specific D2 receptor antagonist) had significantly higher numbers of peripheral MSCs than control
mice. Shone et al. confirmed that approximately 86% of the MSC population did indeed express DA
D2 receptors. By tracking the migration of BrdU-labeled bone marrow-derived MSCs injected into
the systemic circulation, they demonstrated that a significantly higher number of BrdU-labeled MSCs
trafficked to the wound beds of antagonist (eticlopride) treated mice as compared to control mice [42].
VEGF-A is a key growth factor involved in regulating angiogenesis within wound tissue [43,44],
and chemotaxis of human MSCs [45]. Evidence supports that VEGF-A deficiency and poor
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angiogenesis are important pathogenic mechanisms that underpin the delayed wound healing in
people with diabetes mellitus [46,47]. When 1 µM of DA was added to murine MSCs, VEGF-A induced
MSC migration was significantly inhibited. However, when the MSCs were pre-treated with 100 µM
of eticlopride, DA’s inhibitory effect was reversed [42]. The investigators found that DA prevents
VEGF-A induced MSC migration by suppressing the phosphorylation of VEGFR-2 receptors and
phosphorylation of Akt. It was not clear why the authors had not reported an untreated control in
evaluating phosphorylation of VEGFR-2 and Akt as this would have allowed for a better assessment
of the influence of DA independent of VEGF-A stimulation. Regardless, DA appears to inhibit
VEGFR-2 and Akt phorphorylation in VEGF stimulated MSCs, which is reversed by blockade of the
D2 dopamine receptor.
5. Summary
The significance of catecholamines in epidermal function was postulated over 60 years ago, but
the exact role of dopamine has yet to be fully elucidated. Disparate actions of DA on D1 versus D2
receptors in human skin have led to the question of the predominant role of DA in wound healing
(See Table 1).
Table 1. Differential Effects on Wound Healing Mediated by DA D1 versus D2 Receptors.
Agonism of D1 Receptors Agonism of D2 Receptors Antagonism of D2 Receptors
Wound Closure Increases [9] Decreases Increases [20]
Angiogenesis Increases [9] Decreases [11] Increases [20]
Epidermal hyperplasia - Decreases [11]
MSC Mobilization into wound beds Increases [11]
VEGF-A Expression Increases [9] Decreases [25,26]
Cyclic AMP level Increases [7] Decreases [11]
Keratinocyte mitosis Exogenous DA inhibits keratinocyte mitosis in vitro [27]
Regarding angiogenesis, the D1 and D2 receptors appear to respond differently: angiogenesis is
improved by activation of the D1 receptor by its agonists, while for the D2 receptor, it is antagonism
that improves angiogenesis. D1 receptor agonists appear to improve angiogenesis by inducing VEGF
synthesis by fibroblasts. D2 receptors appear to have differential effects in the dermis and the epidermis
as well. In the epidermis, D2 receptor agonists improve skin barrier repair and reduce proliferation of
the keratinocytes. On the other hand, D2 receptor antagonists improve dermal angiogenesis, wound
healing, and MSC trafficking to the wound bed. It is clear that fully characterizing the DA pathway
and D1 receptor in the skin is needed to provide therapeutic insight. A thorough understanding of
catecholamine behavior in the wound microenvironment is important in the setting of wound healing,
and the development of new therapeutic agents to specifically target D1 receptors could be investigated
for use in wound healing. Since both DA agonists and antagonists are approved as drugs for clinical
use for other indications, the pathway to translating these drugs to wound healing indications could
be relatively facilitated. We look forward to those developments.
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